Wall Street Isn't Giving Up on CVS Health -- and Its Valuation Looks Stronger Than Investors Think

CVS reported Q2 revenue of $106.1B (+7.3% YoY) and EPS of $2.31 (+188% YoY), and raised 2026 guidance to at least $414B revenue and $6.84–$7.04 EPS. Offsetting the beat, management flagged Caremark membership declines in 2027 and ongoing 340B headwinds tied to manufacturer restrictions, alongside FTC/antitrust scrutiny and proposed PBM pricing-transparency legislation. Despite guidance uplift, the stock is still down ~12% over the past month, with investors focused on potential PBM margin pressure and healthcare utilization inflation.

Analysis

The market is treating CVS like a margin-story beat, but the more important mechanism is optionality: when one leg is under political pressure, the other two can still reprice the whole equity if cost trends stay contained. At under ~12x forward earnings, the stock is screening as a compressed sum-of-the-parts versus peers, and that discount looks partly like regulatory headline risk rather than a true earnings impairment. The key second-order effect is that PBM pressure could actually favor the largest integrated player over smaller stand-alone PBMs, because scale, data, and cross-subsidization become more valuable when pricing rules tighten.

The immediate risk is that investors are underweighting how fast 340B and antitrust scrutiny can bleed into sentiment even before earnings are hit. Over the next 1-3 months, the main catalyst is whether management can keep revising guidance upward without a concurrent deterioration in Caremark membership or Aetna medical cost ratio; if either rolls over, the rerating thesis fails. Over 6-18 months, the stock is a leverage play on whether vertically integrated healthcare remains defensible, or whether Congress/FTC forces margin sharing that caps the integrated model’s economics.

Contrarian view: the selloff may be overdone if the market is pricing a permanent PBM margin reset while ignoring that CVS can reallocate capital across retail, clinics, and insurance. But the bull case is not free: if utilization inflation or member attrition appears in the next two quarters, the low multiple can become a value trap. Relative to UNH, CVS offers more asymmetry, but only if investors believe the current guidance raise is the start of a trend rather than a one-quarter peak.

Key Decisions for Investors

• Tactical long CVS common or call spread for 1-3 months: buy on post-earnings weakness if the stock stays below the 12x forward multiple; risk/reward is attractive only if subsequent commentary confirms Caremark stability and no Aetna MLR deterioration.
• Pair trade: long CVS / short UNH only as a valuation convergence trade, not a sector bet. Use a modest size and exit if CVS loses its guidance edge or if UNH multiple compresses on broader managed-care pressure.
• Set a watch item on Caremark membership and 340B commentary into the next update. If membership decline accelerates or 340B restrictions widen, fade the long immediately; that would invalidate the thesis faster than EPS revisions.
• If you want a lower-risk expression, buy CVS against a stop tied to the next quarterly medical benefit ratio. A move above the high-80s on MLR would signal the margin inflection is not durable.